WASHINGTON |
WASHINGTON (Reuters) – Health regulators pronounced on Tuesday they have authorized a drug done by Japan’s Shionogi Co to provide women experiencing pain during passionate intercourse.
The U.S. Food and Drug Administration authorized a drug, Osphena, for a form of pain famous as dyspareunia, that is a sign of vulvar and vaginal atrophy due to menopause.
Dyspareunia is compared with disappearing levels of estrogen hormones during menopause. Osphena, famous chemically as ospemifene, is a tablet that acts like estrogen on vaginal tissues to make them thicker and rebate fragile, ensuing in a rebate in pain compared with intercourse.
The drug’s tag includes a boxed warning, a many serious available, alerting patients to an increasing risk of strokes and low capillary thrombosis. Common side effects embody prohibited flashes, vaginal discharge, flesh spasms and extreme sweating.
(Reporting By Toni Clarke; Editing by Gerald E. McCormick)
